Abstract
One of the most prevalent malignant tumors in women is cervical cancer. Conventional chemoradiotherapy was frequently limited by significant side effects and acquired drug resistance. Consequently, there is an urgent need for high-performance biomaterials that effectively suppress tumor growth while exhibiting minimal off-target toxicity. Magnesium alloys represented a promising platform for anti-tumor applications due to their bioactive degradation products. This study developed novel magnesium alloy-mineralized collagen composite scaffolds and systematically evaluated their surface properties. Comprehensive in vitro and in vivo experimental models were used to elucidate the scaffolds' anti-tumor mechanisms. The results of this study demonstrated that magnesium alloy-mineralized collagen composite scaffolds significantly inhibit tumor cell invasion and metastasis while promoting cancer cell death. Based on in vivo and in vitro studies, this study showed that the degradation products of magnesium alloy-mineralized collagen composite scaffolds target epithelial-mesenchymal transition through the Wnt/β-catenin/TCF7 signaling pathway. These findings established a robust experimental foundation for advancing magnesium alloy-mineralized collagen composite scaffolds as next-generation biodegradable adjunctive therapeutic materials for cervical cancer treatment. The synergistic combination of biocompatibility and tumor-targeted activity positions this material as an innovative platform for circumventing shortcomings in existing clinical regimens.